The cost of treating to target: Cross-sectional analysis of patients with poorly controlled type 2 diabetes in Australian general practice

BMC Family Practice

Volumn 14, Issue , 2013, Pages

  Furler, John ^a   Hii, Justin W S ^a   Liew, Danny ^a   Blackberry, Irene ^a   Best, James ^a   Segal, Leonie ^b   Young, Doris ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

Cost; Treatment burden; Treatment gap; Type 2 diabetes

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; AGE; AGED; ARTICLE; AUSTRALIA; CROSS-SECTIONAL STUDY; DEPRESSION; DIABETIC ANGIOPATHY; DIABETIC CARDIOMYOPATHY; DYSLIPIDEMIA; ECONOMICS; FEE; FEMALE; GENERAL PRACTICE; HEART INFARCTION; HUMAN; HYPERTENSION; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEINURIA; RISK FACTOR; TIME; VERY ELDERLY; WAIST CIRCUMFERENCE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; ANTIHYPERTENSIVE AGENTS; AUSTRALIA; CROSS-SECTIONAL STUDIES; DEPRESSION; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC CARDIOMYOPATHIES; DYSLIPIDEMIAS; FEMALE; GENERAL PRACTICE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERTENSION; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PRESCRIPTION FEES; PROTEINURIA; RISK FACTORS; TIME FACTORS; WAIST CIRCUMFERENCE;

MLCS; MLOWN;

EID: 84874695011     PISSN: None     EISSN: 14712296     Source Type: Journal    
DOI: 10.1186/1471-2296-14-32     Document Type: Article

References (38)

1. Australian Institute of Health and Welfare, Diabetes: Australian facts Canberra: AIHW2008 2008
2. Dunstan D, Zimmett P, Welborn T, The final report of the Australian diabetes, obesity and lifestyle study (AusDiab) Melbourne: International Diabetes Institute 2001
3. The obesity-driven rising costs of type 2 diabetes in Australia: projections from the Fremantle diabetes study. Davis WA, Knuiman MW, Hendrie D, Davis TME, Intern Med J 2006 36 3 155 161 10.1111/j.1445-5994.2006.01014.x 16503950
4. National Health Priority Action Council (NHPAC), National chronic disease strategy Canberra: Australian Government Department of Health and Ageing 2006
5. Self-management education for adults with type 2 diabetes: a meta-analysis of the effect on glycemic control. Norris S, Lau J, Smith S, Schmid C, Engelgau M, Diabetes Care 2002 25 7 1159 1171 10.2337/diacare.25.7. 1159 12087014 (Pubitemid 41071167)
6. Systematic review and meta-analysis of randomised controlled trials of psychological interventions to improve glycaemic control in patients with type 2 diabetes. Ismail K, Winkley K, Rabe-Hesketh S, Lancet 2004 363 9421 1589 1597 2004/5/15 10.1016/S0140-6736(04)16202-8 15145632 (Pubitemid 38625661)
7. Effect of a multifactorial intervention on mortality in type 2 diabetes. Gaede P, Lund-Andersen H, Parving H-H, Pedersen O, N Engl J Med 2008 358 5 580 591 18256393 (Pubitemid 351214285)
8. Bonney MA, Carter S, Burns J, Powell-Davies G, Harris MF, National divisions diabetes program, data collation project, volume 3, divisions of general practice-diabetes profiles. Quality of care and health outcomes-collated division data Sydney: Centre for GP Integration Studies, School of Community Medicine, University of New South Wales 2000
9. Austalian primary care collaboratives program. Improvement Foundation, 2012 Accessed July 23 2012]; Available from: http://www.apcc.org.au/
10. Practice incentives program diabetes incentive guidelines - July 2012. 2012 [25 July 2012]. Australian Government Department of Human Services, Available from: http://www.medicareaustralia.gov.au/provider/incentives/pip/ files/9520-1206en.pdf
11. Quality of diabetes care and coronary heart disease absolute risk in patients with type 2 diabetes mellitus in Australian general practice. Wan Q, Harris MF, Jayasinghe UW, Flack J, Georgiou A, Penn DL, Qual Saf Health Care 2006 15 2 131 135 10.1136/qshc.2005.014845 16585115
12. Quality of diabetes care in the UK: comparison of published quality-of-care reports with results of the quality and outcomes framework for diabetes. Khunti K, Gadsby R, Millett C, Majeed A, Davies M, Diabet Med 2007 24 12 1436 1441 10.1111/j.1464-5491.2007.02276.x 17971182 (Pubitemid 350179431)
13. A comparison of chronic illness care quality in US and UK family medicine practices prior to pay-for-performance initiatives. Crosson JC, Ohman-Strickland PA, Campbell S, Phillips RL, Roland MO, Kontopantelis E, Fam Pract 2009 26 6 510 516 10.1093/fampra/cmp056 19748914
14. Patient engagement and coaching for health: the PEACH study-a cluster randomised controlled trial using the telephone to coach people with type 2 diabetes to engage with their GPs to improve diabetes care: a study protocol. Young D, Furler J, Vale M, Walker C, Segal L, Dunning P, BMC Fam Pract 2007 8 (20).
15. Feasibility of centralized measurements of glycated hemoglobin in the Diabetes Control and Complications Trial: a multicenter study. The DCCT Research Group, Clin Chem 1987 33 12 2267 2271 3319291
16. Harris P, Mann L, Phillips P, Snowdon T, Webster C, Diabetes management in general practice: 12th edition Melbourne: Diabetes Australia and the Royal Australian College of General Practitioners 2005
17. Drug treatment and cost of cardiovascular disease in Australia. Ademi Z, Liew D, Chew D, Conner G, Shiel L, Nelson M, Cardiovasc Ther 2009 27 164 172 10.1111/j.1755-5922.2009.00090.x 19689615
18. Pharmaceutical benefits schedule item reports. Period September 2006 to September 2007. Commonwealth of Australia, Accessed 11 May 2012; Available from: https://www.medicareaustralia.gov.au/statistics/pbs-group.shtml
19. Social organisation, stress and health. Brunner EJ, Marmot M, Social determinants of health Oxford; New York: Oxford University Press, Marmot MG, Wilkinson RG, 2 2006 6 30
20. Australian Medicines Handbook 2013 Adelaide: Australian Medicines Handbook Pty Ltd, Rossi S, 2013
21. Expert Group Psychotropic, Therapeutic guidelines (Psychotropics) Melbourne: Therapeutic Guidelines Limited 2008
22. Position statement on lipid management. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand, Heart Lung Circ 2005 14 4 275 291 16361000
23. Management of dyslipidaemia in patients with type 2 diabetes in Australian primary care. Thomas MC, Nestel PJ, Med J Aust 2007 186 3 128 130 17309401 (Pubitemid 46322365)
24. Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. McFarlane SI, Jacober SJ, Winer N, Kaur J, Castro JP, Wui MA, Diabetes care 2002 25 4 718 723 10.2337/diacare.25.4.718 11919131 (Pubitemid 41071193)
25. National trends in treatment of type 2 diabetes mellitus, 1994-2007. Alexander GC, Sehgal NL, Moloney RM, Stafford RS, Arch Intern Med 2008 168 19 2088 2094 2008 10.1001/archinte.168.19.2088 18955637
26. The Health and Social Care Information Centre PaPCS, Prescribing for Diabetes in England: 2005/6 to 2011/12 London: NHS Information Centre 2012
27. Polypharmacy and medication adherence in patients with type 2 diabetes. Grant RW, Devita NG, Singer DE, Meigs JB, Diabetes care 2003 26 5 1408 1412 2003 10.2337/diacare.26.5.1408 12716797 (Pubitemid 36929171)
28. Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians? Shah BR, Hux JE, Laupacis A, Zinman B, van Walraven C, Diabetes Care 2005 28 3 600 606 2005 10.2337/diacare.28.3.600 15735195 (Pubitemid 40326231)
29. Webbie K, OBrien K, AIHW, Use of medicines by Australians with diabetes Canberra: AIHW 2006
30. Competing demands or clinical inertia: the case of elevated Glycosylated hemoglobin. Parchman ML, Pugh JA, Romero RL, Bowers KW, Ann Fam Med 2007 5 3 196 201 2007 10.1370/afm.679 17548846 (Pubitemid 46889995)
31. Management of diabetes: are doctors framing the benefits from the wrong perspective? Wolpert HA, Anderson BJ, BMJ 2001 323 7319 994 996 2001 11679393 (Pubitemid 33016054)
32. Four year follow-up of the multicentre RCT of the COACH study shows that the COACH Programme keeps patients out of hospital. Vale M, Sundararajan V, Best J, Jelinek M, Eur Heart J 2005 26 501 502
33. The idolatry of the surrogate. Yudkin JS, Lipska KJ, Montori VM, Br Med J 2011 343 7995 10.1136/bmj.d7995
34. Intensified glucose lowering in type 2 diabetes: time for a reappraisal. Yudkin JS, Richter B, Gale EAM, Diabetologia 2010 53 10 2079 2085 10.1007/s00125-010-1864-z 20686748
35. Dowrick C, Beyond depression: a new approach to understanding and management Oxford: Oxford University Press 2 2009
36. Tackling therapeutic inertia: role of treatment data in quality indicators. Guthrie B, Inkster M, Fahey T, BMJ (Clinical research ed) 2007 335 7619 542 544 2007 10.1136/bmj.39259.400069.AD (Pubitemid 47477684)
37. We need minimally disruptive medicine. May C, Montori VM, Mair FS, Br Med J 2009 339 2803 10.1136/bmj.b2803
38. Patient reported outcome measures: a model-based classification system for research and clinical practice. Valderas JM, Alonso J, Qual Life Res 2008 17 9 1125 1135 10.1007/s11136-008-9396-4 18836850